BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis

Reference

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Polyatskin IL, Artemyeva AS, Krivolapov YA. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors. Arkh Patol. 2019;81(3):59–65.
   PubMedGoogle Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal antibodies: a review. Curr Clin Pharmacol. 2018;13(2):85–99.
   PubMed Web of Science ®Google Scholar
• Luminari S, Ferrari A, Manni M, et al. Long-Term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with Advanced-Stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36(7):689–696.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shafqat H, Ali S. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56(4):942–950.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol. 2011;48 Suppl 1 (Suppl 1):S4–S11.
   PubMedGoogle Scholar
• Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27(9):1492–1501.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. JCO. 2009;27(26):4378–4384.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116(1):106–114.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473–4479.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-Line treatment of patients with indolent Non-Hodgkin lymphoma or Mantle-Cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J Clin Oncol. 2019;37(12):984–‐991.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–2404.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Cochrane Statistical Methods Group, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in Meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Ahmed M, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD anderson cancer center in the rituximab era. Ann Oncol. 2016;27(5):895–901.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Willenbacher W, et al. Bendamustine plus rituximab versus r-chop as first-line treatment for patients with indolent non-hodgkin's lymphoma: Evidence from a multicenter, retrospective study. Haematologica. 2016;101(276):1107–1114.
   Google Scholar
• Olszewski AJ, Butera JN, Reagan JL, et al. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020;95(4):354–361.
   PubMed Web of Science ®Google Scholar
• Pouyiourou M, Meyer A, Stroux A, on behalf of the East German Study Group for Hematology and Oncology (OSHO), et al. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol. 2020;99(12):2821–2829.
   PubMed Web of Science ®Google Scholar
• Aw A, Coyle K, Bence-Bruckler I, et al. Bendamustine and rituximab versus conventional chemoimmunotherapy as a frontline treatment for patients with indolent B-cell lymphoma: a cost-effectiveness analysis. Blood. 2016;128(22):1186–1186.
   Web of Science ®Google Scholar
• Dewilde S, Woods B, Castaigne JG, et al. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. J Med Econ. 2014;17(2):111–124.
   PubMedGoogle Scholar
• Sabater E, Rueda A, Salar A, et al. Cost-effectiveness analysis of bendamustine plus rituximab as first-line treatment for patients with follicular lymphoma. preliminary results. Haematologica. 2014;99:487–488.
   Web of Science ®Google Scholar
• Shoji A, Yamaguchi S, Oya N, et al. Pcn239 medical cost of rituximab-containing therapy in patients with follicular lymphoma in Japan: R-B is less expensive than R-chop. Value Health. 2019;22:S482.
   PubMed Web of Science ®Google Scholar
• Zhou J, Pathak AK, Brander DM, et al. Differences in health care costs and utilization: BR vs RCHOP in patients with follicular lymphoma. JCO. 2017;35(15_suppl):e19049–e19049.
   Google Scholar
• Wehler EA, Kowal S, Ariza JG, et al. The cost-effectiveness of bendamustine-rituximab (BEN-R) versus R-CHOP for the first line treatment of patients with indolent non-Hodgkin's lymphoma (INHL) in Colombia. Value in Health. 2015;18(7):A818–A9.
   Web of Science ®Google Scholar
• Walewski J, Paszkiewicz-Kozik E, Michalski W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2020;188(6):898–906.
   PubMed Web of Science ®Google Scholar